{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:21:31Z","timestamp":1707524491963},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,15]]},"DOI":"10.7759\/cureus.23171","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T11:37:35Z","timestamp":1647344255000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Clinical and Hematological Parameters of Janus Kinase 2, Calreticulin or Myeloproliferative Leukemia Virus Oncogene Mutant Essential Thrombocythemia and Triple-Negative Essential Thrombocythemia"],"prefix":"10.7759","author":[{"given":"Jale","family":"Y\u0131ld\u0131z","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikmettullah","family":"Batgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/2634853520978210","article-title":"The essential thrombocythemia in 2020: what we know and where we still have to dig deep","volume":"13","author":"Accurso V","year":"2020","unstructured":"Accurso V, Santoro M, Mancuso S, et al.. The essential thrombocythemia in 2020: what we know and where we still have to dig deep. Clin Med Insights Blood Disord. 2020, 13:10.1177\/2634853520978210","journal-title":"Clin Med Insights Blood Disord"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui T","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H, et al.. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018, 8:15. 10.1038\/s41408-018-0054-y","journal-title":"Blood Cancer J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1585239","article-title":"Developments in diagnosis and treatment of essential thrombocythemia","volume":"12","author":"Mora B","year":"2019","unstructured":"Mora B, Passamonti F. Developments in diagnosis and treatment of essential thrombocythemia. Expert Rev Hematol. 2019, 12:159-71. 10.1080\/17474086.2019.1585239","journal-title":"Expert Rev Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21129","article-title":"Prevalence of polycythemia vera and essential thrombocythemia","volume":"83","author":"Ma X","year":"2008","unstructured":"Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008, 83:359-62. 10.1002\/ajh.21129","journal-title":"Am J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-939430","article-title":"Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia","volume":"32","author":"Johansson P","year":"2006","unstructured":"Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006, 32:171-3. 10.1055\/s-2006-939430","journal-title":"Semin Thromb Hemost"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4021\/jocmr1125w","article-title":"Etiology of thrombocytosis in a general medicine population: analysis of 801 cases with emphasis on infectious causes","volume":"4","author":"Rose SR","year":"2012","unstructured":"Rose SR, Petersen NJ, Gardner TJ, Hamill RJ, Trautner BW. Etiology of thrombocytosis in a general medicine population: analysis of 801 cases with emphasis on infectious causes. J Clin Med Res. 2012, 4:415-23. 10.4021\/jocmr1125w","journal-title":"J Clin Med Res"},{"key":"ref7","article-title":"Epidermiological, diagnostic, therapeutic and prognostic aspects of essential thrombocithemia in a retrospective study of the GIMMC group in two thousand patients","volume":"90","author":"Gugliotta L","year":"1997","unstructured":"Gugliotta L, Marchioli R, Fiacchini M, et al.. Epidermiological, diagnostic, therapeutic and prognostic aspects of essential thrombocithemia in a retrospective study of the GIMMC group in two thousand patients. Blood. 1997, 90:1551.","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000521","article-title":"Low-risk essential thrombocythemia: a comprehensive review","volume":"5","author":"Robinson AJ","year":"2021","unstructured":"Robinson AJ, Godfrey AL. Low-risk essential thrombocythemia: a comprehensive review. Hemasphere. 2021, 5:e521. 10.1097\/HS9.0000000000000521","journal-title":"Hemasphere"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0041-8","article-title":"Essential thrombocythemia treatment algorithm 2018","volume":"8","author":"Tefferi A","year":"2018","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 2018, 8:2. 10.1038\/s41408-017-0041-8","journal-title":"Blood Cancer J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl T","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, et al.. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013, 369:2379-90. 10.1056\/NEJMoa1311347","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.637116","article-title":"Triple-negative essential thrombocythemia: clinical-pathological and molecular features. A single-center cohort study","volume":"11","author":"Cattaneo D","year":"2021","unstructured":"Cattaneo D, Croci GA, Bucelli C, et al.. Triple-negative essential thrombocythemia: clinical-pathological and molecular features. A single-center cohort study. Front Oncol. 2021, 11:637116. 10.3389\/fonc.2021.637116","journal-title":"Front Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia","volume":"132","author":"Cheung B","year":"2006","unstructured":"Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol. 2006, 132:244-5. 10.1111\/j.1365-2141.2005.05858.x","journal-title":"Br J Haematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell PJ","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G, et al.. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005, 366:1945-53. 10.1016\/S0140-6736(05)67785-9","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701885537","article-title":"JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera","volume":"49","author":"Zhang S","year":"2008","unstructured":"Zhang S, Qiu H, Fischer BS, et al.. JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera. Leuk Lymphoma. 2008, 49:696-9. 10.1080\/10428190701885537","journal-title":"Leuk Lymphoma"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.2014.0136","article-title":"Impact of JAK2V617F mutational status on phenotypic features in essential thrombocythemia and primary myelofibrosis","volume":"33","author":"Y\u00f6nal \u0130","year":"2016","unstructured":"Y\u00f6nal \u0130, Da\u011flar-Aday A, Akadam-Teker B, Y\u0131lmaz C, Nal\u00e7ac\u0131 M, Yavuz AS, Sarg\u0131n FD. Impact of JAK2V617F mutational status on phenotypic features in essential thrombocythemia and primary myelofibrosis. Turk J Haematol. 2016, 33:94-101. 10.4274\/tjh.2014.0136","journal-title":"Turk J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi E","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, et al.. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014, 123:1544-51. 10.1182\/blood-2013-11-539098","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2010.02199.x","article-title":"JAK2 mutations in Asian patients with essential thrombocythaemia","volume":"41","author":"Wong GC","year":"2011","unstructured":"Wong GC, Kam GL, Koay ES. JAK2 mutations in Asian patients with essential thrombocythaemia. Intern Med J. 2011, 41:191-6. 10.1111\/j.1445-5994.2010.02199.x","journal-title":"Intern Med J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi AM","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, et al.. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007, 110:840-6. 10.1182\/blood-2006-12-064287","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11653","article-title":"Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia","volume":"93","author":"Antonioli E","year":"2008","unstructured":"Antonioli E, Guglielmelli P, Poli G, et al.. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008, 93:41-8. 10.3324\/haematol.11653","journal-title":"Haematologica"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.118299","article-title":"Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations","volume":"100","author":"Al Assaf C","year":"2015","unstructured":"Al Assaf C, Van Obbergh F, Billiet J, et al.. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica. 2015, 100:893-7. 10.3324\/haematol.2014.118299","journal-title":"Haematologica"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/90295-comparison-of-clinical-and-hematological-parameters-of-janus-kinase-2-calreticulin-or-myeloproliferative-leukemia-virus-oncogene-mutant-essential-thrombocythemia-and-triple-negative-essential-thrombocythemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:35:49Z","timestamp":1707507349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/90295-comparison-of-clinical-and-hematological-parameters-of-janus-kinase-2-calreticulin-or-myeloproliferative-leukemia-virus-oncogene-mutant-essential-thrombocythemia-and-triple-negative-essential-thrombocythemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.23171","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,15]]}}}